Objectives: To evaluate the efficacy and safety of induction regimens "7+3"- Cytarabine + doxorubicin for acute myeloid leukemia (AML). Patient and methods: restrospective cross sectional study on 30 AML patients who underwent Doxorubicin 30 mg/m2/day x 3 days plus Cytarabine 200 mg/m2/day x 7 days. Results: complete response rate (CR) was 46,7 percent; partial response (PR) was 33,3 percent and noneresponse (NR) was 20 percent. The clinical symptoms improved: anemia rate descresed from 93,3 percent to 46,7 percent, hemorrhage rate descresed from 46,7 percent to 20 percent vesus before treatment. The incidence of adverse events symptoms (AES) of "7+3" regimen was: vomiting and nausea grade 2 and 3 were 6.7 percent and 20.6 percent, alopecia grade 2, 3 were 26 percent and 23.3 percent, granulocytopenia grade 3 and 4 were 30 percent and 60 percent, thrombocytopenia grade 3 and 4 were 26,7 percent and 56,7 percent. Conclusions: The "7+3" induction regimen with standart cytarabin dose results in a high response rate and manageable AES in AML patients.
- Đăng nhập để gửi ý kiến